Lite Strategy closed at $1.11 on Nov 4, up 7.21%, 50.7% below its 52-week closing high. Volume of 93.0K shares was 0.28× its 20-day average (below normal).
Split-adjusted performance: -20.9% over one month, -6.3% over six months, -41.9% over one year.
Short interest was 108.5K shares at the Oct 15 settlement, down 41.4% from the prior report (0.4% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LITSLite Strategy | $1.12 | +7.21% | −6.3% | — | — | — | $33.9M | |
| BTMDBiote | $1.19 | +6.25% | −45.9% | −9.5% | −14.8% | 5.8 | $34.1M | Compare |
| RMTIRockwell Medical, Inc. (DE) | $8.00 | −1.11% | −1.2% | +10.6% | −7.5% | — | $32.2M | Compare |
| IBOImpact BioMedical | $4.20 | +4.48% | −47.6% | −57.1% | −23300.0% | 45.5 | $35.9M | Compare |
| IXHLIncannex Healthcare Limited | $2.55 | +1.80% | −48.1% | — | — | — | $32.0M | Compare |
| NNVCNanoViricides | $1.42 | −0.94% | −3.0% | — | — | — | $36.2M | Compare |
| VERUVeru | $2.16 | 0.00% | −2.7% | — | — | — | $36.8M | Compare |
| GRCEGrace Therapeutics | $1.82 | −1.09% | −23.2% | — | — | — | $38.3M | Compare |
| SCYXSCYNEXIS | $3.88 | −1.52% | −50.6% | −82.8% | 3147.7% | — | $38.6M | Compare |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
